Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression
Thoracic Cancer · 2023
DOI: 10.1111/1759-7714.15116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Tara L Peters und 5 weiteren Autor:innen. Beteiligte Einrichtung: Enliven Therapeutics, Inc., Boulder, Colorado, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Axl Receptor Tyrosine Kinase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
The vast majority of patients with ROS1 positive non‐small cell lung cancer (NSCLC) derive clinical benefit from currently approved ROS1 therapies, including crizotinib and entrectinib. However, a small proportion of patients treated with ROS1 inhibitors fail to derive any clinical benefit and demonstrate rapid disease progression. The biological mechanisms underpinning intrinsic resistance remain poorly understood for oncogene‐driven cancers.
Methods
We generated a patient‐derived cell line, CUTO33, from a ROS1 therapy naive patient with CD74‐ROS1+ NSCLC, who ultimately did not respond to a ROS1 inhibitor. We evaluated a panel of ROS1+ patient‐derived NSCLC cell lines and used cell‐based assays to determine the mechanism of intrinsic resistance to ROS1 therapy.
Results
The CUTO33 cell line expressed the CD74‐ROS1 gene fusion at the RNA and protein level. The ROS1 fusion protein was phosphorylated at baseline consistent with the known intrinsic activity of this oncogene. ROS1 phosphorylation could be inhibited using a wide array of ROS1 inhibitors, however these inhibitors did not block cell proliferation, confirming intrinsic resistance in this model and consistent with the patient's lack of response to a ROS1 inhibitor. CUTO33 expressed high levels of AXL, which has been associated with drug resistance. Combination of an AXL inhibitor or AXL knockdown with a ROS1 inhibitor partially reversed resistance.
Conclusions
In summary, we demonstrate that AXL overexpression is a mechanism of intrinsic resistance to ROS1 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Enliven Therapeutics, Inc., Boulder, Colorado, USA.
- Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- OnKure Therapeutics, Inc., Boulder, Colorado, USA.
- Cell Technologies Shared Resources, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
ORCID-Profile: Nan Chen
Förderung
- NCI NIH HHS
Zitieren
APA
Peters, T. L., Chen, N., Tyler, L. C., Le, A. T., Dimou, A., & Doebele, R. C. (2023). Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15116
Vancouver
Peters TL, Chen N, Tyler LC, Le AT, Dimou A, Doebele RC. Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15116
BibTeX
@article{Peters2023,
author = {Peters, Tara L and Chen, Nan and Tyler, Logan C and Le, Anh T and Dimou, Anastasios and Doebele, Robert C},
title = {Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression},
journal = {Thoracic Cancer},
year = {2023},
doi = {10.1111/1759-7714.15116}
}
EUVIMED